Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Evaluating Bu Yang Huanwu Decoction For Early Diabetic Vascular Disease

maanantai 15. kesäkuuta 2026 päivittänyt: Xuanwu Hospital, Beijing

Evidence-Based Evaluation and New Drug Translation Research of Early Intervention With the Classic Traditional Chinese Medicine Formula Bu Yang Huanwu Decoction for Preventing and Treating Diabetic Lower Extremity Vascular Disease

The goal of this clinical trial is to learn if adding a Traditional Chinese Medicine formula, Bu Yang Huanwu Decoction (specifically the capsule form called Hua Yu Wan Capsule), to standard treatment can help prevent leg pain at rest or foot ulcers in people with diabetic lower extremity vascular disease. The main questions it aims to answer are:

Does adding Hua Yu Wan Capsule to standard treatment lower the chance of developing leg pain at rest or foot ulcers after one year, compared to standard treatment alone?

Is the treatment combination safe for participants?

Researchers will compare two groups:

Group 1 (Experimental): Standard treatment (including aspirin, and medicines for blood sugar and cholesterol control) plus Hua Yu Wan Capsule.

Group 2 (Control): Standard treatment alone.

Participants in this study will:

Be adults aged 18 to 70 years with diabetes and early to moderate lower extremity vascular disease (confirmed by tests like the Ankle-Brachial Index or ABI).

Be randomly assigned to one of the two treatment groups.

Take their assigned treatment for 6 months.

Attend clinic visits at 1, 3 and 6 months during treatment, and again at 6 and 12 months after treatment ends for check-ups and tests.

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Ehdot

Interventio / Hoito

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

300

Vaihe

  • Vaihe 3

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Beijing, Kiina
        • Xuanwu Hospital
        • Ottaa yhteyttä:

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

  • Aikuinen
  • Vanhempi Aikuinen

Hyväksyy terveitä vapaaehtoisia

Ei

Kuvaus

Inclusion Criteria:

  1. Aged 18 to 70 years (inclusive), male or female.
  2. Diagnosed with diabetes mellitus according to the Chinese Diabetes Society (2024) Guidelines.
  3. Glycated hemoglobin (HbA1c) < 12%, with recent fasting blood glucose < 7.0 mmol/L OR postprandial blood glucose < 10.0 mmol/L, and triglycerides < 1.7 mmol/L.
  4. Diagnosed with LEAD, meeting the following criteria:

    Rutherford Classification 2, 3, or 4.

    Resting ABI ≤ 0.90, OR for patients with exertional symptoms and resting ABI > 0.90, a post-exercise treadmill test showing an ABI decrease of ≥15%.

    Evidence of lower limb arterial stenosis or occlusion confirmed by duplex ultrasound, CTA, MRA, or DSA.

  5. TCM Pattern Diagnosis: Must conform to the TCM syndrome of Qi Deficiency and Blood Stasis, as defined by the study's TCM diagnostic criteria (referencing "Practical Diagnostic Criteria for Blood Stasis Syndrome" and "Integrated Chinese and Western Medicine Peripheral Vascular Disease"):

    Main Symptom: Lower limb weakness, or feeling of heaviness/discomfort after prolonged walking.

    Secondary Symptoms: Shortness of breath/lassitude in speaking; dry mouth with desire to drink; scaly skin.

    Tongue & Pulse: Tongue with teeth marks, pale-purple with petechiae/ecchymosis; thin and choppy pulse.

    (Diagnosis confirmed by meeting 1 main symptom OR 2 secondary symptoms, assessed by a qualified TCM practitioner.)

  6. Voluntarily signs the Informed Consent Form (ICF) and is willing and able to comply with all study procedures and visits.

Exclusion Criteria:

  1. Known bleeding disorders or history of intracranial hemorrhage.
  2. Current use of anticoagulants (e.g., warfarin, dabigatran, factor Xa inhibitors).
  3. Presence of active infection.
  4. Severe cardiac abnormalities on resting ECG (e.g., heart failure, ventricular tachycardia, ventricular fibrillation, multifocal ventricular contractions, prolonged corrected QT interval).
  5. History of acute coronary syndrome ≤ 12 months requiring dual antiplatelet therapy.
  6. Chronic liver disease (Child-Turcote-Pugh score ≥5) or chronic kidney disease stages 4-5 (eGFR < 30 mL/min/1.73m²).
  7. History of malignancy (except cured basal cell carcinoma).
  8. Moderate to severe anemia, polycythemia vera, or any hyperviscosity syndrome.
  9. Planned lower limb revascularization or amputation.
  10. Concurrent or planned use of medicinal products containing Veratrum species.
  11. Pregnant or lactating women, or women of childbearing potential not using highly effective contraception.
  12. Known allergy or hypersensitivity to any component of the study medication (Qilong Capsules, aspirin).
  13. Patients with psychiatric disorders or judged to be uncooperative.
  14. Currently participating in another drug clinical trial or using therapies with similar purported effects.
  15. Any other condition deemed by the investigator to make the participant unsuitable for the trial.

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Ennaltaehkäisy
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Ei mitään (avoin tarra)

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Standard Therapy and Hua Yu Wan Capsule

1. Standard Baseline Medication: Hua Yu Wan Capsule: 5g, taken orally two times daily. Treatment Duration: The combined regimen is administered continuously for 6 months (divided into four 6-week cycles).

2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments without receiving the study drug.

A modern preparation of the classic Traditional Chinese Medicine formula Bu Yang Huanwu Decoction. Each capsule contains 0.2g of the herbal extract.

Dosage and Route: 2 capsules, taken orally three times daily.

Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 12 months.
Active Comparator: Standard Therapy Alone
  1. Standard Baseline Medication:

    Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 6 months.

  2. Follow-up: After the 6-month treatment period, participants enter a 12-month follow-up phase for observational assessments.
Aspirin: 100 mg, administered orally once daily. Treatment Duration: The standard medication is administered continuously for 12 months.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Incidence of new-onset ischemic rest pain or foot ulcer at 12 months of treatment.
Aikaikkuna: From enrollment to the end of treatment at 12 months

Ischemic Rest Pain: Persistent pain in the toes/forefoot at rest, typically nocturnal, worsened by elevation, relieved by dependency, often with pallor/coldness.

Foot Ulcer: Ischemic skin breakdown/tissue necrosis in pressure areas (toes, heel, sole), with well-defined edges, dry/necrotic base, poor perfusion, and absence of significant inflammation.

Assessment Method: Clinical evaluation by investigator at each scheduled visit. Confirmed by physical examination and documented photographically if applicable.

From enrollment to the end of treatment at 12 months

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of participants with investigator-confirmed new-onset ischemic rest pain or clinically confirmed ischemic foot ulcer at 12 months
Aikaikkuna: From enrollment to the end of treatment at 12 months
Composite primary outcome defined as the number of participants who develop either: (1) new-onset ischemic rest pain confirmed by investigator clinical assessment, or (2) ischemic foot ulcer confirmed by physical examination with photographic documentation when applicable, by Month 12.
From enrollment to the end of treatment at 12 months
Number of participants with major adverse cardiovascular and cerebrovascular events (MACCE)
Aikaikkuna: From enrollment to the end of treatment at 12 months
MACCE is defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
From enrollment to the end of treatment at 12 months
Number of participants hospitalized during the study
Aikaikkuna: From enrollment to the end of treatment at 12 months
Number of participants who require inpatient hospitalization for any cause during the study period, as confirmed by hospital admission records or investigator documentation. Repeated hospitalizations in the same participant will be counted once unless otherwise specified in the statistical analysis plan.
From enrollment to the end of treatment at 12 months
Number of participants who die during the study
Aikaikkuna: From enrollment to the end of treatment at 12 months
Number of participants who die from any cause during the study period, as confirmed by medical records, death certificates, hospital documentation, or investigator follow-up. Each participant will be counted once.
From enrollment to the end of treatment at 12 months
Change in ankle-brachial index(ABI) from baseline
Aikaikkuna: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in ankle-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in toe-brachial index (TBI) from baseline
Aikaikkuna: reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in toe-brachial index from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
reported at Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in intermittent claudication distance from baseline
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in intermittent claudication distance from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Rate of clinically driven lower-extremity arterial revascularization after treatment
Aikaikkuna: From enrollment to the end of treatment at 12 months
Rate of clinically driven lower-extremity arterial revascularization after treatment, including endovascular or open surgical revascularization: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months
Change in Vascular Quality of Life Questionnaire-6 score from baseline
Aikaikkuna: From enrollment to the end of treatment at 12 months
Change in Vascular Quality of Life Questionnaire-6 score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months
Change in Traditional Chinese Medicine syndrome score from baseline
Aikaikkuna: From enrollment to the end of treatment at 12 months
Change in Traditional Chinese Medicine syndrome score from baseline: Month 1, Month 3, and Month 6 during the treatment period; Month 6 and Month 12 during the follow-up period.
From enrollment to the end of treatment at 12 months

Muut tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Number of participants with clinically significant bleeding events
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with bleeding events during the study. Unit of Measure: Participants
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal physical examination findings
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal findings on physical examination.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal hematology test results
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in hematology parameters, including white blood cell count, red blood cell count, hemoglobin, and platelet count.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal urinalysis results
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in urinalysis parameters, including urine white blood cells, urine red blood cells, urine glucose, and urine protein.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal liver function test results
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in liver function parameters, including alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, and gamma-glutamyl transferase.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal renal function test results
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in renal function parameters, including blood urea nitrogen or urea, and serum creatinine.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal coagulation test results
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormalities in coagulation function parameters, including thrombin time, prothrombin time, activated partial thromboplastin time, international normalized ratio, and fibrinogen.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Body Temperature From Baseline
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in body temperature from baseline at each scheduled assessment. Unit of Measure: Degrees Celsius
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Pulse Rate From Baseline
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in pulse rate from baseline at each scheduled assessment. Unit of Measure: Beats per minute
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Respiratory Rate From Baseline
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in respiratory rate from baseline at each scheduled assessment. Unit of Measure: Breaths per minute
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Systolic Blood Pressure From Baseline
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in systolic blood pressure from baseline at each scheduled assessment. Unit of Measure: mmHg
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in Diastolic Blood Pressure From Baseline
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Change in diastolic blood pressure from baseline at each scheduled assessment. Unit of Measure: mmHg
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with clinically significant abnormal 12-lead electrocardiogram findings
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Measure Description: Number of participants with clinically significant abnormal findings on 12-lead electrocardiogram, as assessed by the investigator.

Unit of Measure: Participants

Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with positive pregnancy test results
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of female participants of childbearing potential with positive pregnancy test results during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Allergic Reactions
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with allergic reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Gastrointestinal Adverse Reactions
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with gastrointestinal adverse reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of Participants With Nervous System Adverse Reactions
Aikaikkuna: Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18
Number of participants with nervous system adverse reactions during the study.
Baseline, Month 1, Month 3, Month 6, Month 12, and Month 18

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Sponsori

Yhteistyökumppanit

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Maanantai 1. kesäkuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Tiistai 1. helmikuuta 2028

Opintojen valmistuminen (Arvioitu)

Maanantai 1. tammikuuta 2029

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Keskiviikko 11. helmikuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 15. kesäkuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Maanantai 22. kesäkuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Maanantai 22. kesäkuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 15. kesäkuuta 2026

Viimeksi vahvistettu

Maanantai 1. kesäkuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • BYHWT-EDVD

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

PÄÄTTÄMÄTÖN

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .